APEX1 and osteosarcoma: In addition, miR-765 was found to sensitize osteosarcoma cells lines (HOS and 9901) and tumour xenografts to cisplatin due to downregulation of Ape1 [372], making targeting APE1 through miRNA a treatment option for resistant osteosarcoma.